Zanubrutinib Combination Therapies Show Promise in High-Risk CLL/SLL Treatment
核心洞察
Zanubrutinib combined with venetoclax achieved 100% overall response rate and 48% complete response rate in treatment-naïve high-risk CLL (搜索)/SLL (搜索) patients with del(17p) and/or TP53 (搜索) mutations in the SEQUOIA phase 3 trial.
The combination of sonrotoclax and zanubrutinib demonstrated 97% overall response rate with 57% complete response rate across all doses in relapsed/refractory CLL (搜索)/SLL (搜索) patients, with 85% achieving undetectable minimal residual disease.
Both combination therapies showed manageable safety profiles with no new safety concerns identified, positioning zanubrutinib as a potential backbone therapy for high-risk CLL (搜索)/SLL (搜索) treatment.
Zanubrutinib, a next-generation BTK (搜索) inhibitor, is demonstrating significant efficacy when combined with BCL2 (搜索) inhibitors in treating high-risk chronic lymphocytic leukemia (搜索) (CLL (搜索)) and small lymphocytic lymphoma (搜索) (SLL (搜索)), according to recent clinical trial data presented at the European Hematology Association 2024 Hybrid Congress.
SEQUOIA Trial Results in Treatment-Naïve Patients
The randomized, multicenter, global SEQUOIA phase 3 trial (NCT03336333) investigated zanubrutinib in combination with venetoclax in 66 treatment-naïve patients with CLL (搜索)/SLL (搜索) harboring del(17p) and/or TP53 (搜索) mutations. These genetic alterations represent high-risk features associated with poor treatment outcomes and early relapse.
Patients received zanubrutinib 160 mg twice daily for 3 months, followed by the same zanubrutinib dose combined with venetoclax using ramp-up dosing to 400 mg once daily for 12 to 24 cycles until progressive disease, unacceptable toxicity, or confirmed undetectable minimal residual disease (MRD).
Among 65 response-evaluable patients, the overall response rate (ORR) reached 100%. The complete response (CR) with incomplete hematopoietic recovery (CRi) rate was 48%, comprising 46% CR and 2% CRi. Undetectable MRD was achieved in 59% of patients, and median progression-free survival (PFS) was not reached. The 12- and 24-month PFS estimates were 95% and 94%, respectively.
Safety analysis revealed that 97% of patients experienced at least one treatment-emergent adverse effect (TEAE), with 44% experiencing grade ≥3 non-hematologic TEAEs. The study authors reported no new safety concerns with the combination.
Sonrotoclax Combination Shows Promise in Relapsed/Refractory Setting
The phase 1 BGB-11417-101 study (NCT04277637) evaluated sonrotoclax, a next-generation BCL-2 inhibitor, in combination with zanubrutinib in 47 patients with relapsed/refractory CLL (搜索)/SLL (搜索). Sonrotoclax is described as more selective and pharmacologically potent than venetoclax, with a shorter half-life and no drug accumulation.
At a median follow-up of 19.3 months, the combination achieved a 97% ORR with a CR/CRi rate of 57% across all dose levels. In the 320-mg cohort, which was established as the recommended phase 2 dose, the ORR was 100% with a CR/CRi rate of 73%.
The patient population had challenging characteristics: 53% had 17p deletions and/or TP53 (搜索) mutations, 68% had unmutated IGHV, and patients had received a median of 1 prior line of therapy. Among patients evaluable for MRD status, 85% achieved undetectable MRD at data cutoff, with responses deepening over time.
Safety Profile and Clinical Implications
The sonrotoclax-zanubrutinib combination demonstrated a manageable safety profile. Among all patients, 94% experienced any-grade TEAEs, 51% had grade 3 or higher TEAEs, and 28% experienced serious TEAEs. The most common adverse events included contusion (32%), neutropenia (27%), COVID-19 (28%), diarrhea (28%), and fatigue (26%). Notably, no cases of tumor lysis syndrome, atrial fibrillation, or febrile neutropenia were observed.
No dose-limiting toxicities occurred with the combination, and the maximum tolerated dose was not reached. Forty-six of 47 patients remained on study treatment at the time of analysis.
Clinical Significance for High-Risk CLL/SLL
CLL (搜索)/SLL (搜索) represents the most common adult leukemia in Western populations, comprising 25% to 30% of cases in the United States. Patients with del(17p) and/or TP53 (搜索) mutations face particularly challenging outcomes, often experiencing treatment resistance or early relapse with standard therapies.
"SEQUOIA has shown that [zanubrutinib] is a highly effective monotherapy treatment for TN CLL (搜索) patients, including those with high-risk markers like del(17p) and/or TP53 (搜索) mutation," said Mehrdad Mobasher, MD, MPH, chief medical officer, Hematology at BeiGene (搜索). "With one of the largest pools of high-risk patients of any published study to date, SEQUOIA arm D demonstrates how BCL2 (搜索) inhibitor therapies can complement BRUKINSA as a backbone therapy to achieve deep clinical response even in this patient population."
The findings position zanubrutinib as a potential backbone therapy for combination approaches in high-risk CLL (搜索)/SLL (搜索), with both venetoclax and sonrotoclax showing complementary mechanisms of action that may optimize treatment outcomes while maintaining acceptable safety profiles.